Lixte Biotechnology Warrants
LIXTW
LIXTW was delisted on the 26th of November, 2025.
3 hedge funds and large institutions have $3.6K invested in Lixte Biotechnology Warrants in 2025 Q3 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, 1 reducing their positions, and 2 closing their positions.
149% more capital invested
Capital invested by funds: $1.45K → $3.6K (+$2.16K)
1.7% less ownership
Funds ownership: 3.37% → 1.67% (-1.7%)
25% less funds holding
Funds holding: 4 → 3 (-1)
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$172 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$722 |
| 2 |
CS
Clear Street
New York
|
-$206 |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$3 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CS
1
Clear Street
New York
| $3.12K | -$206 | -1,036 | -5% |
|
|
NFSG
2
Newbridge Financial Services Group
Boca Raton,
Florida
| $361 | – | – | – |
|
|
3
UBS Group
Zurich,
Switzerland
| $125 | +$172 | +867 | New |
|
|
4
Citadel Advisors
Miami,
Florida
| – | -$722 | -25,231 | Closed |
|
|
5
Bank of America
Charlotte,
North Carolina
| – | -$3 | -100 | Closed |
|
LIXTW Hedge Fund Activity: Q3 2025 in Review
3 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Lixte Biotechnology Warrants (LIXTW) for Q3 2025, worth a combined $3.6K — up 149% from $1.45K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of LIXTW and 1 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 0 added.
The largest buyer was UBS Group, opening a new position worth an estimated $172. The largest seller was Citadel Advisors, exiting entirely with an estimated $722 sold.
- 3 institutional investors held Lixte Biotechnology Warrants (LIXTW) as of Q3 2025, down from 4 in Q2 2025.
- Funds reported $3.6K of Lixte Biotechnology Warrants stock for Q3 2025, up 149% quarter-over-quarter.
- 1 fund opened new Lixte Biotechnology Warrants positions in Q3 2025 and 2 closed out, a net change of -1 holder.
- The largest Lixte Biotechnology Warrants buyer in Q3 2025 was UBS Group, an estimated $172 added.
- The largest Lixte Biotechnology Warrants seller in Q3 2025 was Citadel Advisors, an estimated $722 sold.
Based on aggregated 13F filings for Q3 2025.